Long-term follow-up of persons diagnosed with multidrug-resistant TB in Chennai, India, 2013-2020

Surie, Diya and Sathyanarayanan, Mukesh Kumar and Lavanya, J and Smith, J S and Shanmugam, S K and Tamilzhalagan, S and Selvaraj, A and Ramesh, G and Tripathy, S and Khaparde, S D and Ho, C S and Hall-Eidson, P J and Ranganathan, Uma Devi K. and Selvaraju, Sriram and Moonan, Patrick K. (2024) Long-term follow-up of persons diagnosed with multidrug-resistant TB in Chennai, India, 2013-2020. Long-term follow-up of persons diagnosed with multidrug-resistant TB in Chennai, India, 2013-2020, 28(1) (54–56). pp. 1-5.

Text 202418.pdf - Published Version Download (303kB)

Abstract

India has the largest number of multidrug-resistant TB (MDR-TB) cases, defined as Mycobacterium tuberculosis resistant to at least isoniazid (INH) and rifampicin (RIF).1 However, less than half of all persons with MDR-TB in India successfully complete treatment.1 Although initial end-of-treatment outcomes offer a standardised time point to assess the effect of treatment, these tend to underestimate the overall burden of unfavourable long-term outcomes among persons treated for TB.2,3 The long-term outcomes of persons diagnosed with MDR-TB in India, including the proportion with recurrent TB disease or mortality, are unknown. This analysis was conducted under programmatic conditions in a high-burden setting, with no regular check-ups after treatment. The results can be used to show the burden of recurrent illness and death following treatment, and can be used as a benchmark to measure improvement.

Affiliation:	ICMR- National Institute for Research in Tuberculosis
Item Type:	Article
Uncontrolled Keywords:	tuberculosis; drug resistance; recurrence; relapse; reinfection; mortality
Subjects:	Tuberculosis > Laboratory Research > Immunological
Divisions:	Basic Science Research > Immunology
Depositing User:	Mrs. N Lakshmi
Date Deposited:	02 Aug 2024 14:19
Last Modified:	02 Aug 2024 14:19
URI:	http://eprints.nirt.res.in/id/eprint/2012

Actions (login required)

View Item